On April 15, two years after Eisai requested a marketing license for lecanemab in Europe, the European Commission has greenlit its use. The biologic’s long path included an initial rejection from the ...

The blood-brain barrier border protects the brain by regulating the flow of molecules, peptides, and cells, but it also keeps out many therapeutics. Now, researchers have harnessed the power of a ...

Of the 20,000+ human genes, none has greater influence on late-onset Alzheimer’s disease than APOE. But why do certain variants of this lipid transporter protect the brain, while others endanger it? A ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...

Single-cell transcriptomics aficionados have raised the bar again. In a study published in Nature on July 24, scientists led by Li-Huei Tsai and Manolis Kellis at Massachusetts Institute of Technology ...

A record 4,700 people from 70 countries attended the 18th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 5 to 9 in Lisbon, Portugal. Those who attended this hybrid ...

Part 1 of 2. Click here for Part 2. As Alzheimer’s clinicians across the U.S. started offering a disease-modifying treatment to their patients, uptake at first was slow but is now speeding up. Six ...

Part 2 of 2. Click here for Part 1. What happens in the brain of a person with fatal ARIA? Researchers now have one of their first detailed looks at the pathology of this rare and calamitous condition ...

Not so long ago, a blood test for Alzheimer’s disease seemed a pipe dream. Now, after years of study, the field is awash with sensitive assays that signal the proteopathic culprits Aβ and tau ...

The first direct-to-consumer Alzheimer’s disease blood test has arrived. Quest Diagnostics, a worldwide diagnostic service headquartered in Secaucus, New Jersey, announced on July 31 that it would ...

Why do some people with amyloid plaques decline, while others do not? In the May 29 Nature Medicine, researchers led by Tharick Pascoal at the University of Pittsburgh laid some of the blame on ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...